Search results for "Hormonal"

showing 10 items of 136 documents

Quality of life and adjuvant tamoxifen treatment in breast cancer patients

2009

About two-thirds of all breast cancer patients are treated with adjuvant hormonal therapy. Side effects of tamoxifen and their effects on physical, emotional and social functioning have been shown to impair the quality of life. Aim of this paper was to evaluate the side effects and level of influence on the physical, emotional and social functioning caused by tamoxifen treatment. For assessment of quality of life an own questionnaire was designed. Between January 2001 and December 2003, 136 women with breast cancer and adjuvant tamoxifen therapy were included in this study. Data of side effects, physical and mental health and patients' self-evaluation identified detrimental effects on patie…

AdultOncologymedicine.medical_specialtyAntineoplastic Agents Hormonalmedicine.medical_treatmentBreast NeoplasmsBreast cancerQuality of lifeSurveys and QuestionnairesInternal medicineBody ImagemedicineHumansskin and connective tissue diseasesAgedAged 80 and overChemotherapyAdjuvant tamoxifenbusiness.industryMiddle Agedmedicine.diseaseMental healthTamoxifenOncologyChemotherapy AdjuvantQuality of LifeHormonal therapyFemalebusinessAdjuvantTamoxifenmedicine.drugEuropean Journal of Cancer Care
researchProduct

A multicenter phase III prospective randomized trial of high-dose epirubicin in combination with cyclophosphamide (EC) versus docetaxel followed by E…

2011

Background: The Gruppo Oncologico Italia Meridionale 9902 trial compared four cycles of high-dose epirubicin plus cyclophosphamide (EC) with four cycles of docetaxel (Taxotere, D) followed by four cycles of EC as adjuvant treatment of node-positive breast cancer. Patients and methods: Patients were randomly assigned to EC (E 120 mg/m 2 , C 600 mg/m 2 , arm A) for four cycles or four cycles of D (100 mg/m 2 ) followed by four cycles of EC (arm B), both regimens every 21 days. Hormone receptor-positive patients were given hormonal therapy for 5 years. Primary end point was 5-year disease-free survival (DFS). Secondary objectives were overall survival (OS) and safety. Results: There were 750 p…

AdultOncologymedicine.medical_specialtyCyclophosphamideBreast NeoplasmsDocetaxelDisease-Free SurvivalBreast cancerInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansProspective StudiesProspective cohort studyCyclophosphamideSurvival analysisEpirubicinGynecologyDose-Response Relationship Drugbusiness.industryCarcinomaHazard ratioOriginal ArticlesHematologyMiddle Agedmedicine.diseaseSurvival AnalysisItalyOncologyDocetaxelLymphatic MetastasisHormonal therapyFemaleTaxoidsLymph NodesbusinessAlgorithmsmedicine.drugEpirubicinAnnals of Oncology
researchProduct

Acute abdomen due to endometriosis in a premenopausal woman taking tamoxifen.

2003

Tamoxifen exhibits agonistic properties on the uterus. We describe a premenopausal woman who, while having tamoxifen due to a diagnosis of in situ ductal carcinoma, developed endometriosis requiring surgery.

AdultSelective Estrogen Receptor Modulatorsmedicine.medical_specialtyAntineoplastic Agents HormonalEndometriosisUterusEndometriosisBreast NeoplasmsCarcinomamedicineHumansskin and connective tissue diseasesGynecologybusiness.industryCarcinoma Ductal BreastObstetrics and GynecologyDuctal carcinomamedicine.diseaseAntiestrogenAbdominal PainOvarian CystsTamoxifenmedicine.anatomical_structureReproductive MedicinePremenopauseAcute abdomenAcute DiseaseFemalemedicine.symptombusinesshormones hormone substitutes and hormone antagonistsTamoxifenmedicine.drugEuropean journal of obstetrics, gynecology, and reproductive biology
researchProduct

Sexual self-schema: a cognitive schema and its relationship to choice of contraceptive method among Polish women

2019

Objectives: The aim of the study was to examine sexual self-schema in women using different methods of contraception. Methods: Women (N = 560) aged 18–55 years were divided into two groups: those who used hormonal contraception (n = 285) and those who used non-hormonal contraception (n = 275). Participants were assessed using the Sexual Self-Schema Scale (SSSS), the Well-Matched Marriage Questionnaire and the Hospital Anxiety and Depression Scale and were also asked to fill in a structured questionnaire, giving information on their socioeconomic status, reproductive and medical history, sexual behaviours, psychosexual orientation, sexual experience and type of contraception used. Results: W…

AdultSelf-schemaAdolescentSexual BehaviorpsychologyYoung AdultCognitionSurveys and QuestionnairesSchema (psychology)Body ImageContraceptive Agents FemaleHumansMedicinePharmacology (medical)cognitive schemabusiness.industryObstetrics and GynecologyCognitionMiddle AgedSelf ConceptContraceptionCross-Sectional StudiesLogistic ModelsSexual PartnersContraceptive Agents HormonalReproductive MedicineFemalewomenPolandbusinesssexual self-schemaClinical psychologyThe European Journal of Contraception & Reproductive Health Care
researchProduct

Hormonal contraceptives and breast cancer: Clinical data.

2018

Abstract The endocrine background of breast cancer has raised questions about the increase in risk that might bear the use of hormonal contraceptives. This has been a particular issue in the case of young women, who constitute the population of contraceptive consumers. Observational studies have been the main source of evidence, which has mainly limited to the combined estrogen-progestogen preparations, the popular pill. Studies in the 80′s and 90′s of the past century found a small, around a 20%, increase in risk. The translation in absolute number of excess cases has been exiguous because the prevalence of the disease is relatively small in premenopausal women. Moreover, the risk slowly s…

AdultTime Factorsmedicine.medical_treatmentPopulationGenes BRCA2Genes BRCA1PhysiologyBreast NeoplasmsDiseaseContraceptives Oral Hormonal03 medical and health sciencesYoung Adult0302 clinical medicineBreast cancerRisk FactorsmedicineEndocrine systemHumanseducationeducation.field_of_study030219 obstetrics & reproductive medicineProgestogenbusiness.industryObstetrics and GynecologyCancermedicine.diseaseReproductive Medicine030220 oncology & carcinogenesisPillRelative riskMutationFemalebusinessEuropean journal of obstetrics, gynecology, and reproductive biology
researchProduct

Evidence of jak2 val617phe positive essential thrombocythemia with splanchnic thrombosis during estroprogestinic treatment

2008

The discovery of the Janus kinase 2 Val617Phe mutation has brought new insights into the development of myeloproliferative disorders; however, the pathogenesis of essential thrombocythemia and its related thrombotic complications has not been completely understood. Although the Janus kinase 2 Val617Phe mutation confirms the initially suspected clonal character of the disease, factors influencing clonal transformation and expansion in the bone marrow have not been fully detected. Furthermore, patients affected by essential thrombocythemia who are carriers of the Janus kinase 2 Val617Phe mutation show a higher incidence of venous thromboembolism both before, and at the time of diagnosis, comp…

Adultmedicine.medical_specialtyMutation MissenseOral contraceptiveEssential thrombocythemiaGastroenterologyContraceptives Oral HormonalPathogenesisMesenteric VeinsPortal thrombosisMyeloproliferative DisordersInternal medicinemedicineHumansPlateletSplanchnic CirculationJanus kinase 2Janus kinase 2biologyessential thrombocythemia Janus kinase 2 oral contraceptives portal thrombosisKinaseEssential thrombocythemiaVascular diseasebusiness.industryThrombosisHematologyGeneral Medicinemedicine.diseaseThrombocytopeniaThrombosisEndocrinologybiology.proteinFemalebusiness
researchProduct

The influence of oral contraceptives on the composition of bile.

1982

The increased risk of cholelithiasis during intake of oral contraceptives may be due to estrogen-induced saturation of the bile with cholesterol. In a randomized, prospective, crossed-over double-blind study 20 healthy women after roentgenological exclusion of gall-stones received either 1.0 mg of norethindrone acetate and 50 microgram ethinyl estradiol daily - as usual in oral contraception - for 21 days with 7 days of placebo treatment in each cycle or one fifth of this hormone dose in form of a continuous daily medication. After a 4 month's treatment the medication form was crossed-over. At the beginning of the study, before the cross-over and after the study bile was collected by duoden…

Adultmedicine.medical_specialtyNauseamedia_common.quotation_subjectGallbladder diseasePhysiologyEthinyl EstradiolContraceptives Oral HormonalMenstruationchemistry.chemical_compoundCholelithiasisInternal medicineDrug DiscoverymedicineBileHumansProspective cohort studyGenetics (clinical)Menstrual cyclemedia_commonbusiness.industryCholesterolGeneral Medicinemedicine.diseaseEndocrinologyCholesterolchemistryHormonal contraceptionVomitingMolecular MedicineFemalemedicine.symptomNorethindronebusinessContraceptives OralKlinische Wochenschrift
researchProduct

Cycle scheduling for in vitro fertilization with oral contraceptive pills versus oral estradiol valerate: a randomized, controlled trial

2013

Abstract Background Both oral contraceptive pills (OCPs) and estradiol (E2) valerate have been used to schedule gonadotropin-releasing hormone (GnRH) antagonist in vitro fertilization (IVF) cycles and, consequently, laboratory activities. However, there are no studies comparing treatment outcomes directly between these two pretreatment methods. This randomized controlled trial was aimed at finding differences in ongoing pregnancy rates between GnRH antagonist IVF cycles scheduled with OCPs or E2 valerate. Methods Between January and May 2012, one hundred consecutive patients (nonobese, regularly cycling women 18–38 years with normal day 3 hormone levels and <3 previous IVF/ICSI attempts)…

Adultmedicine.medical_specialtyPregnancy Ratemedia_common.quotation_subjectPopulationPhysiologyFertilization in VitroCycle schedulingReproductive technologyGonadotropin-releasing hormoneValerateContraceptives Oral Hormonallaw.inventionGonadotropin-Releasing HormoneEndocrinologyRandomized controlled trialPregnancylawInternal medicineGnRH antagonistHumansMedicineeducationMenstrual CycleMenstrual cyclemedia_commonchemistry.chemical_classificationeducation.field_of_studyEstradiolOral contraceptivesbusiness.industryResearchEstradiol valerateEstrogen pretreatmentObstetrics and GynecologyPregnancy rateEndocrinologychemistryReproductive MedicineIVFFemalebusinessmedicine.drugDevelopmental BiologyReproductive Biology and Endocrinology
researchProduct

Contraception in diabetic women: an Italian study

2005

Abstract Over 1 year, a survey on contraception and obstetric history was performed on a cohort of 667 Caucasian fertile diabetic women (446, type 1 and 201, type 2) living in Italy. Results: Of these women, 30.4% used hormonal contraceptives, 12.0% intra-uterine device (IUD), 10.7% declared they used no contraception, 47.0% only utilised barrier and/or natural methods. However, irrespective of their previous contraceptive strategy, 7.2% of all the studied population was surgically sterilized during caesarean section. Hormonal contraception: Of these women, 60.4% was prescribed by a gynaecologist, 11.2% by a diabetologist, 15% by both of them and 13.4% by others. The proportion using oral c…

Adultmedicine.medical_specialtytype 1 diabetesEndocrinology Diabetes and Metabolismmedicine.medical_treatmentPopulationdiabetic pregnancycontraception; diabetic pregnancy; type 1 diabetes; type 2 diabetesWhite PeopleCohort StudiesEndocrinologyInternal MedicinemedicineHumansCaesarean sectioneducationGynecologyPregnancyeducation.field_of_studyDiabetic RetinopathyGeographyMarital Statusbusiness.industryObstetricsSmokingGeneral Medicinemedicine.diseaseDiabetes Mellitus Type 1Diabetes Mellitus Type 2ItalycontraceptionHormonal contraceptionFamily planningCohortFemaletype 2 diabetesbusinessDeveloped countryCohort studyDiabetes Research and Clinical Practice
researchProduct

Associations of Sex Hormones and Hormonal Status With Arterial Stiffness in a Female Sample From Reproductive Years to Menopause

2021

Objective: Loss of sex hormones has been suggested to underlie menopause-associated increment in cardiovascular risk. We investigated associations of sex hormones with arterial stiffness in 19–58-years-old women. We also studied associations of specific hormonal stages, including natural menstrual cycle, cycle with combined oral contraceptives (COC) and menopausal status with or without hormone therapy (HT), with arterial stiffness. Methods: This study includes repeated measurements of 65 healthy women representing reproductive (n=16 natural, n=10 COC-users) and menopause (n=5 perimenopausal, n=26 postmenopausal, n=8 HT-users) stages. Arterial stiffness outcomes were aortic pulse wave veloc…

AdultnaisetAdolescentvaihdevuodetBlood PressurekuukautisetPulse Wave Analysisreproductive hormoneshormonaaliset tekijätYoung AdultEndocrinologyVascular StiffnessHeart Ratewomen’s healthHumanspulse wave analysisArterial PressureGonadal Steroid HormonesMenstrual CycleOriginal ResearchsukupuolihormonitEstradiolhormonal contraceptionvascular stiffnessMiddle Agedhormone replacement therapyikääntyminenkuukautiskiertoFollicular Phasevascular aginghormonihoitosydän- ja verisuonitauditFemaleFollicle Stimulating HormoneMenopausemenstruation
researchProduct